StockWireNews
Low Float Past Champ: Gather Key Details Now On This Nasdaq Breakout Idea Before Everyone Else
Full Report Arrives At 8:00PM EST Tonight
Sign Up To My SMS Update System - Directions Below
March 15th
Greetings Readers,
We've got a past champ back on alert.
Brought to your attention previously, all it did was run $1.50+ and produce an intraday surge of approximately 50+%.
Not bad, but that's just the tip of the iceberg.
This company is looking to disrupt a potential $1.5Bn market with its treatment currently in a phase 2 clinical trial.
And that's not the only $Bn market this Nasdaq profile is looking to disrupt in the years ahead.
Before Wall Street catches on to what this profile is working on, it's your time to get them on radar first.
At 8:00PM EST tonight, you'll be able to do just that with my complete report.
Now, to get you prepared so you're able to soak in this report on the fly, here's a few key details I've compiled ahead of time. Check them out:
3 Major Potential Catalysts - Key Details On This Nasdaq Past Champ
#1. We're looking at another low float idea. Just like my profile for Tuesday's opening bell that ran approximately 16% intraday, volatility could be in the cards based on this profile's tiny float (fewer than 5Mn shares).
#2. The company ended 2022 in a strong cash position that they feel puts them in a prime position to achieve multiple milestones in the year ahead.
#3. Oversold technicals signal the potential for a significant reversal/bounce in the near term. At close on Tuesday, this profile had a 9-Day and 14-Day Relative Strength Index below 35%.
With a 14-Day Raw Stochastic and 14-Day Williams %R hovering in oversold territory too, now may be the ultimate time to get this Nasdaq past champ back on radar.
Since there's time now, do this:
